FATE Stock Analysis: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$2.70
0.28 (11.57%)
▲
5d:
+25.0%
30d:
-4.93%
90d:
+138.94%
HOLD
MODERATE Confidence
Analysis Updated: Jun 30, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: FATE is 8.9% above its trading range ($2.48). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: FATE is 8.9% above its trading range ($2.48). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $2.70, which is considered extended relative to its 30-day fair value range of $1.91 to $2.48.
Technical Outlook: Technically, FATE is in a strong uptrend. Immediate support is located at $1.82, while resistance sits at $2.88. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: FATE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.41 (+100.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FATE is in a strong uptrend. Immediate support is located at $1.82, while resistance sits at $2.88. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: FATE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.41 (+100.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.91 -
$2.48
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.6%)
- BULLISH: Trading 100.4% below Wall St target ($5.41)
- CAUTION: Extended 8.9% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.91 -
$2.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.88
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.73
Wall Street Target
$5.41
(+100.4%)
Revenue Growth (YoY)
-20.3%
Share & Embed Analysis
Last updated: June 30, 2026 7:58 PM ET
Data refreshes hourly during market hours. Next update: 8:58 PM
Data refreshes hourly during market hours. Next update: 8:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahram Valamehr
SELL
5190 shares
2026-01-09
Cindy Tahl
SELL
10589 shares
2026-01-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 60 BUY |
